AMER PHARMA PTN, (APPX) Stock Research Free Stock Rating

Company Profile

American Pharmaceutical Partners, Inc. (APP) engages in the development, manufacture, and marketing of injectable pharmaceutical products in North America. It focuses primarily on the injectable oncology, anti-infective, and critical care markets. APP’s oncology products include Pamidronate disodium, used to treat hypercalcemia associated with a malignancy, with or without bone metastates, and Paget’s disease; Mesna, used to treat the side effects associated with chemotherapy drugs; Cisplatin, used to treat metastatic testicular or ovarian cancer, Hodgkin’s disease, nonHodgkin’s lymphoma, brain tumors, and cancer of the nervous system; Carboplatin is indicated for the initial treatment of ovarian carcinoma in combination with other chemotherapeutic agents, and for the palliative treatment of recurrent ovarian carcinoma after prior chemotherapy; and Ifosfamide, used to treat germ cell testicular cancer. The company’s injectable anti-infective products include Cefoxitin used for gynecological infections; Vancomycin, used to treat Staph, Strep, or other infections; Doxycycline, which is used to treat anthrax, Rocky Mountain Spotted Fever, typhus, and mycoplasma pneumonia; Cefotaxime, which is used to treat intra-abdominal infections, such as peritonitis, central nervous system infections, bacteremia and septicemia, and infections of the skin, bone, and joints; and Gentamicin, which is used to treat endocarditis, septicemia and bacterial bone, respiratory tract, soft tissue, urinary tract, and other infections. Its injectable critical care products include Injectable heparin, which is a blood thinner used to prevent and treat blood clotting; and Oxytocin, which is used to induce labor at term and control postpartum bleeding. APP manufactures its products in three basic forms: liquid, powder, and lyophilized or freeze-dried. The company holds the North American rights to sell ABRAXANE, a proprietary nanoparticle injectable oncology product that is a patented formulation of paclitaxel and other cancer therapies. Its products are used in hospitals, long term care facilities, alternate care sites, and clinics. The company was formed in 1996 and is headquartered in Los Angeles, California. American Pharmaceutical Partners, Inc. is 67.9% owned by American BioScience, Inc., as of December 31, 2004.

Latest Headlines

The Year's Top Stock (at Motley Fool)

APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius (Business Wire)

APP Pharmaceuticals Announces Completion of Acquisition by Fresenius (Business Wire)

APP PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Baxter Ready to Sop Up Additional Revenue (at Motley Fool)

The Year's Top Stock (at Motley Fool)

APP PHARMACEUTICALS, INC. Financials (EDGAR Online Financials)

APP PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (EDGAR Online)

APP PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (EDGAR Online)

Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More (at CNBC)